AMD-8664

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H38N6
Molecular Weight	410.5987
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C(NCC1=NC=CC=C1)C2=CC=C(CN3CCCNCCNCCCNCC3)C=C2

InChI

InChIKey=CWJJHESJXJQCJA-UHFFFAOYSA-N

InChI=1S/C24H38N6/c1-2-13-29-24(5-1)20-28-19-22-6-8-23(9-7-22)21-30-17-4-12-26-15-14-25-10-3-11-27-16-18-30/h1-2,5-9,13,25-28H,3-4,10-12,14-21H2

HIDE SMILES / InChI

Molecular Formula	C24H38N6
Molecular Weight	410.5987
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17522382 | https://www.ncbi.nlm.nih.gov/pubmed/12556213 | http://adisinsight.springer.com/drugs/800014613

AMD8664 (1-pyridin-2-yl-N-[4-(1,4,7-triazacyclotetradecan-4- ylmethyl)benzyl]methanamine) is an antagonist of CXCR4 receptor. It has therapeutic potential in the treatment of HIV. AMD8664 is an effective suppressor of choroidal neovascularization.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
C-X-C chemokine receptor type 4 5 Target ID: CHEMBL2107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17522382 \| https://www.ncbi.nlm.nih.gov/pubmed/12556213 \| http://adisinsight.springer.com/drugs/800014613	Antagonist 2849

Conditions

Condition	Modality	Targets	Highest Phase	Product
HIV-1 infection 156 Sources: http://adisinsight.springer.com/drugs/800014613	Primary		Not Provided 511	Unknown Approved Use Unknown
Choroidal neovascularization 2 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17522382	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization.	2007-10	17522382
The therapeutic potential of CXCR4 antagonists in the treatment of HIV.	2003-02	12556213

Patents

Sample Use Guides

In Vivo Use Guide

mice: intravitreous injections 1 ul of AMD8664 (0.9 mM) or daily periocular injections of 5 ul AMD8664 (0.9 mM)

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:10:04 GMT 2025` Edited by `admin` on `Mon Mar 31 22:10:04 GMT 2025`
Record UNII	IMD9Z48ZTT
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

2-PYRIDINEMETHANAMINE, N-((4-(1,4,8,11-TETRAAZACYCLOTETRADEC-1-YLMETHYL)PHENYL)METHYL)-

Preferred Name

English

AMD-8664

Code

English

AMD8664

Code

English

Code System Code Type Description

CAS

185991-24-6

Created by admin on Mon Mar 31 22:10:04 GMT 2025 , Edited by admin on Mon Mar 31 22:10:04 GMT 2025

PRIMARY

PUBCHEM

483559

Created by admin on Mon Mar 31 22:10:04 GMT 2025 , Edited by admin on Mon Mar 31 22:10:04 GMT 2025

PRIMARY

FDA UNII

IMD9Z48ZTT

Created by admin on Mon Mar 31 22:10:04 GMT 2025 , Edited by admin on Mon Mar 31 22:10:04 GMT 2025

PRIMARY

Related Record Type Details


					B5GGG91KI4

C-X-C CHEMOKINE RECEPTOR TYPE 4

TARGET -> INHIBITOR

Amount:


					859A956UY8

HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

TARGET ORGANISM->INHIBITOR

Amount:

Related Record Type Details


					IMD9Z48ZTT

AMD-8664

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/17522382 | https://www.ncbi.nlm.nih.gov/pubmed/12556213 | http://adisinsight.springer.com/drugs/800014613

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17522382 | https://www.ncbi.nlm.nih.gov/pubmed/12556213 | http://adisinsight.springer.com/drugs/800014613